Salim Syed
Stock Analyst at Mizuho
(2.24)
# 2,675
Out of 4,931 analysts
75
Total ratings
42.37%
Success rate
-1.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTX Nkarta | Maintains: Outperform | $16 → $14 | $2.01 | +596.52% | 8 | Jun 10, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $103 → $84 | $35.25 | +138.30% | 7 | May 29, 2025 | |
| BIIB Biogen | Maintains: Outperform | $207 → $169 | $127.75 | +32.29% | 16 | May 7, 2025 | |
| AMGN Amgen | Maintains: Neutral | $235 → $280 | $284.70 | -1.65% | 8 | May 7, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $100 → $117 | $110.28 | +6.09% | 7 | May 5, 2025 | |
| WVE Wave Life Sciences | Maintains: Outperform | $19 → $22 | $8.13 | +170.60% | 5 | Nov 21, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $30.01 | +443.15% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $10.96 | +64.23% | 4 | Aug 16, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $34 | $17.95 | +89.42% | 1 | Apr 9, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $99 | $55.96 | +76.91% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $53 | $45.95 | +15.34% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $0.88 | +2,275.83% | 5 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $168 → $36 | $21.22 | +69.65% | 1 | Nov 16, 2022 |
Nkarta
Jun 10, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $2.01
Upside: +596.52%
Cytokinetics
May 29, 2025
Maintains: Outperform
Price Target: $103 → $84
Current: $35.25
Upside: +138.30%
Biogen
May 7, 2025
Maintains: Outperform
Price Target: $207 → $169
Current: $127.75
Upside: +32.29%
Amgen
May 7, 2025
Maintains: Neutral
Price Target: $235 → $280
Current: $284.70
Upside: -1.65%
Gilead Sciences
May 5, 2025
Maintains: Outperform
Price Target: $100 → $117
Current: $110.28
Upside: +6.09%
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19 → $22
Current: $8.13
Upside: +170.60%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $30.01
Upside: +443.15%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $10.96
Upside: +64.23%
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $17.95
Upside: +89.42%
CRISPR Therapeutics AG
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $55.96
Upside: +76.91%
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $45.95
Upside: +15.34%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $0.88
Upside: +2,275.83%
Nov 16, 2022
Maintains: Buy
Price Target: $168 → $36
Current: $21.22
Upside: +69.65%